Compounds useful for treating neurological disorders

Abstract

The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.

1 . A method for treating neuropathic pain or neuronal degeneration, in a mammal comprising administering to the mammal, a therapeutically effective amount of a compound selected from:
 (a) propyl isopropyl acetic acid (PIA); and   (b) propyl isopropylacetamide (PID),   
       or a stereoisomer, a racemic mixture, a non-racemic mixture of stereoisomers, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. 
     
     
         2 . The method according to  claim 1 , wherein the compound is (2R)- or (2S)-propyl isopropylacetic acid. 
     
     
         3 . The method according to  claim 1 , wherein the compound is (2R)- or (2S)-propyl isopropylacetamide. 
     
     
         4 . The method according to  claim 1 , wherein the compound is a racemic or non-racemic mixture of (2R)- and (2S)-propyl isopropylacetic acid. 
     
     
         5 . The method according to  claim 1 , wherein the compound is a racemic or non-racemic mixture of (2R)- and (2S)-propyl isopropylacetamide. 
     
     
         6 . The method according to  claim 1 , wherein the route of administration of the compound is selected from oral, parenteral, topical, transdermal, mucosal, rectal and buccal administration. 
     
     
         7 . The method according to  claim 6 , wherein the route of administration of the compound is selected from oral and parenteral administration. 
     
     
         8 . The method according to  claim 7 , wherein the parenteral route of administration is selected from intravenous, intramuscular, intraperitoneal and subcutaneous administration. 
     
     
         9 . The method according to  claim 1 , wherein the mammal is a human.